期刊论文

ShenXianYiGanLing combined with Telbivudine for 60 cases of Patients with HBeAg Positive Chronic Hepatitis B Randomized Controlled Study

中文

实用中医内科杂志

1671-7813

2012

26

5

47-49

10.3969/j.issn.1671-7813.2012.05.22

本校为第一机构

[目的]观察参仙乙肝灵联合替比夫定治疗HBeAg阳性慢性乙型肝炎疗效.[方法]使用随机平行对照方法,将60例门诊HBeAg阳性慢性乙型肝炎患者随机分两组.单用组30例替比夫定600mg口服,1次/d.联合组30例参仙乙肝灵片8粒/次,3次/d；替比夫定600mg口服,1次/d.均连续给药52周.治疗12周、24周、52周检测HBV DNA、乙型肝炎e抗原(HBeAg)、中医症侯改善、肝功能指标变化及药物不良反应,随访1年,判定疗效.[结果]HBV - DNA阴特率及HBeAg/HBeAb血清转换率12周两组均无明显差异(P＞0.05)；24周、52周联合组均优于单用组(P＜0.05)；中医症侯疗效联合组优于单用组(P＜0.05)；治疗12周、24周、52周两组肝功能均有明显...

[ Objective ] To observe the effects of ShenXianYiGanLing combined with telbivudine in patients with HBeAg positive chronic hepatitis B. [ Methods ] 60 cases of HBeAg positive CHB were randomly divided into two groups. In combined group （30cases） , telbivudine was given 600 mg once a day and ShenXianYiGanLing 8 pieces of each time. three times a day. In telbivudine group （30 cases） , telbivudine was given alone.Clinical evaluation and laboratory detection were performed at the 12,24,52 weeks of the follow up period. [ Results] At 12 weeks, ...